|
EP3608317A1
(en)
|
2012-01-12 |
2020-02-12 |
Yale University |
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN106456699B
(en)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
Compositions and methods for inhibiting anti-apoptotic Bcl-2 proteins as anti-aging agents
|
|
JP2017522388A
(en)
|
2014-07-22 |
2017-08-10 |
バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ |
Compositions and methods for selectively depleting senescent cells
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
AU2016209349B2
(en)
|
2015-01-20 |
2020-05-07 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the Androgen Receptor
|
|
GB201504314D0
(en)
*
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
CN108601764A
(en)
*
|
2015-03-18 |
2018-09-28 |
阿尔维纳斯股份有限公司 |
The Compounds and methods for of enhancing degradation for target protein
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
KR20180097530A
(en)
*
|
2015-11-02 |
2018-08-31 |
예일 유니버시티 |
Proteolysis Targeting Chimera compounds and methods for their manufacture and use
|
|
CN109152933B
(en)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
Compounds that induce degradation of anti-apoptotic BCL-2 family proteins and uses thereof
|
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
|
AU2017313085A1
(en)
|
2016-08-19 |
2019-03-14 |
Beigene Switzerland Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
JP6899993B2
(en)
*
|
2016-10-04 |
2021-07-07 |
国立医薬品食品衛生研究所長 |
Heterocyclic compound
|
|
HRP20230414T1
(en)
|
2016-10-11 |
2023-07-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
CA3209295A1
(en)
|
2016-11-01 |
2018-06-07 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
|
EP3689868B1
(en)
|
2016-12-01 |
2023-09-27 |
Arvinas Operations, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
KR102564201B1
(en)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
Compounds and methods for targeted degradation of rapidly progressive fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CA3047586A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
EP3573977A4
(en)
|
2017-01-26 |
2020-12-23 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
AU2018290532A1
(en)
|
2017-06-26 |
2019-11-21 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
|
US11623932B2
(en)
|
2017-09-22 |
2023-04-11 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CA3085645C
(en)
*
|
2017-12-13 |
2024-01-16 |
Shanghaitech University |
Alk protein degraders and their use in cancer therapy
|
|
US10519152B2
(en)
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
EP3731869A4
(en)
|
2017-12-26 |
2021-09-22 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3743066A4
(en)
|
2018-01-26 |
2021-09-08 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
CN112218859A
(en)
|
2018-04-04 |
2021-01-12 |
阿尔维纳斯运营股份有限公司 |
Modulators of proteolysis and related methods of use
|
|
WO2019241231A1
(en)
*
|
2018-06-11 |
2019-12-19 |
Abhishek Sharma |
Antiestrogen compounds
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020027225A1
(en)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
Heterocyclic compound
|
|
CN112912376A
(en)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases
|
|
MX2021006154A
(en)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof.
|
|
CN113454106A
(en)
|
2019-02-21 |
2021-09-28 |
洛奇治疗公司 |
Survival targeting chimeric (SURTAC) molecules
|
|
CA3135802A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
|
KR20220008869A
(en)
|
2019-05-14 |
2022-01-21 |
누베이션 바이오 인크. |
Anticancer Nuclear Hormone Receptor-Targeting Compounds
|
|
CN114867727A
(en)
|
2019-07-17 |
2022-08-05 |
阿尔维纳斯运营股份有限公司 |
TAU protein targeting compounds and related methods of use
|
|
TW202131930A
(en)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3165168A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP2023509394A
(en)
|
2019-12-23 |
2023-03-08 |
カイメラ セラピューティクス， インコーポレイテッド |
SMARCA decomposing agents and their use
|
|
MX2022011602A
(en)
|
2020-03-19 |
2023-01-04 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof.
|
|
TW202210483A
(en)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Crystalline forms of irak degraders
|
|
CN112094307A
(en)
*
|
2020-09-28 |
2020-12-18 |
深圳市术理科技有限公司 |
Compound for target ubiquitination degradation of ER alpha protein and application thereof
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
AU2022246058A1
(en)
|
2021-03-23 |
2023-10-05 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2023076161A1
(en)
|
2021-10-25 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|